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                           INTRODUCTION 
 
 
          Is it not disgraceful that a person should, by reason that extraordinary 
arthritis, be unable to use his hands and should need somebody else to bring 
food to his mouth and to perform the other necessities for him… and even if 
overlooks the disgraceful aspect of this, yet one cannot overlook the pain 
these people suffer, night and day.    
                                                                                      Galen (128 – 200 A.D) 
 
          Rheumatoid arthritis (RA) is the most common inflammatory arthritis 
and hence an important cause of potentially presenting disability. 
Rheumatoid arthritis is a chronic multi system disease of unknown cause. 
Although there are a variety of systemic manifestations, the characteristic 
feature of Rheumatoid arthritis is a persistent inflammatory synovitis, 
usually involving peripheral joints in a symmetric distribution. The potential 
of synovial inflammation to cause cartilage damage and bone erosions and 
subsequent changes in the joint integrity is the hallmark of the disease. 
Despite its destructive potential, the course of RA can be quite variable. 
Some patients may experience only a mild oligoarticular illness of brief 
duration with minimal joint damage, where as others will have a relentless 
progressive polyarthritis with marked functional impairment.    
 
            Long- term survival of patients with rheumatoid arthritis is shorter 
compared with the general population or control population without RA1 
Among the different causes of death, increased mortality from heart disease 
with high mortality from congestive cardiac failure was reported in many 
studies. 1,2 Necropsy studies showed a high incidence of pericardial, 
myocardial and endocardial involvement in RA patients. 3 However, cardiac 
disease is clinically silent and is rarely a life threatening complication in RA. 
Cardiac failure is the result of either systolic or diastolic dysfunction, or 
both. Left ventricular diastolic dysfunction is usually attributable to common 
structural abnormalities such as hypertrophy or interstitial fibrosis and 
impaired myocyte relaxation resulting from ischemia. 4 In RA, the cardiac 
disease can present in various forms in relation with granulomatosis and 
vasculitis. In patients with RA, all layers of the heart can be inflamed and 
pericarditis is the most common form of involvement. Moreover valvular 
disease, myocardial involvement, coronary vasculitis and diastolic 
dysfunction can be identified. 
                             
                           Lung involvement in rheumatoid arthritis is not uncommon, 
comprising pleural effusion, interstitial fibrosis, pulmonary rheumatoid 
nodules, and involvement of small airways. 
 
                   Pulmonary hypertension has also been described in RA patients. 
This is usually the result of RA- associated lung disease.5 Isolated case 
reports of primary pulmonary hypertension have also been published.6 
Primary pulmonary hypertension is often clinically silent until well 
advanced. Sub clinical pulmonary hypertension may be more common in 
rheumatoid arthritis, since Dawson et al.7 reported that 21% of all the 
rheumatoid arthritis patients had pulmonary hypertension identified by 
echocardiography, without significant cardiac disease or lung disease 
evident upon pulmonary function testing. In fact, at the initial stages of 
pulmonary hypertension, symptoms may be absent or may be quite 
unspecific, causing this diagnosis to be missed or delayed.  
 
           Doppler echocardiography is a sensitive and non-invasive method of 
detecting cardiac abnormalities and systolic and/or diastolic function and for 
detecting pulmonary hypertension.         
 
            There have been no studies from the Indian sub continent on the 
prevalence of left ventricular filling abnormalities and pulmonary 
hypertension in Rheumatoid arthritis patients. So we decided to study these 
parameters and investigated whether they correlate with the disease duration.  
             
                          
 
 
 
 
 
 
 
 
 
 
  
 
                              AIMS AND OBJECTIVES      
 
1. To study the prevalence of cardiovascular manifestations using 
echocardiography in rheumatoid arthritis (RA) patients without clinically 
evident cardiovascular manifestations. 
 
2. To evaluate the left ventricular filling abnormalities, analyzing transmitral 
flow in rheumatoid arthritis (RA) patients without clinically evident 
cardiovascular manifestations with special regard to disease duration. 
 
3. To study the prevalence of pulmonary hypertension using Doppler 
echocardiography in rheumatoid arthritis (RA) patients without clinically 
evident cardiovascular manifestations and to correlate it with the duration of 
disease. 
 
 
 
                                  REVIEW OF LITERATURE 
 
 
Historical review: 
 
                  The delineation of Rheumatoid Arthritis (RA) as a disease 
entity in the contemporary medical literature began to emerge in the 18 th 
century. It was Alfred Baring Garrod (1859) who first used the term 
Rheumatoid arthritis. 
                     In the early days of modern medicine, RA like other diseases 
of unknown causes was thought to result from foci of infection. (Hunter 
1901: Wilcox 1935). The microscopic observation of fibrinoid changes in 
rheumatoid joints and nodules prompted Klemperor et al in 1942 to consider 
that the disease might result from diffuse primary degeneration of collagen. 
This led to the inclusion of RA in the group of connective tissue diseases, 
however this theory was hampered by the observations that the 
hydroxyproline and collagen content of the subcutaneous nodule was 
normal.    
                   The discovery by Waaler (1940) of IgM Rheumatoid factor in 
the blood of patients was the first immunological marker of rheumatoid 
disease to be recognized. Examinations of ancient medical literature and 
mediaeval paintings have yielded evidence of RA prevalent in those periods.  
 Prevalence:  
            The prevalence of RA is approximately 0.8 % of population (range 
0.3 to 2.1%): women are affected approximately three times more often than 
men. The prevalence increases with age, and sex differences diminish in the 
older age groups. RA is seen throughout the world and affects all races. 
However, the incidence and severity seem to be less in rural sub Saharan 
Africa and in Caribbean blacks. The onset is more frequent during the fourth 
and fifth decades of life, with 80 % of all patients developing the disease 
between the ages of 35 and 50. 
 
Genetic Factors: 
           Family studies indicate a genetic predisposition. Approximately 10 % 
of patients with RA will have an affected first degree relative. Moreover 
monozygotic twins are at least four times more likely to be concordant for 
RA than dizygotic twins. The class II major histocompatibilty complex allele 
HLA-DR4 and related alleles are known to be major genetic risk factors for 
RA. In some groups, including Asian Indians like ours, however there is no 
association between the development of RA and HLA-DR4. In these 
individuals there is an association between RA and the closely related HLA-
DR1. 
             Additional genes in the HLA-D complex may also convey altered 
susceptibility to RA. Certain HLA-DR alleles, including HLA-DR5, HLA-
DR2, HLA-DR3 and HLA-DR7 may protect against the development of RA 
in that they tend to be found at lower frequency in RA patients than in 
controls. Moreover, polymorphisms in the tumor necrosis factor (TNF) and 
the interleukin (IL) 10 genes are also associated with RA, as is a region on 
chromosome 3 (3q13). 
 
Environmental factors:       
                  A number of possible causative agents have been suggested, 
including Mycoplasma, Epstein-Barr virus, Cytomegalovirus, parvovirus 
and rubella virus. The mechanism by which these produce damage is not 
clear, probably by producing persistent infection of articular structures and 
by acting as super antigens. Of all the potential environmental structures, the 
only one clearly associated with the development of RA is cigarette 
smoking.  
 
 
Pathology and Pathogenesis: 
                The precise mechanism by which bone and cartilage destruction 
occurs has not been completely resolved. Although the synovial fluid 
contains a number of enzymes potentially able to degrade cartilage, the 
majority of destruction occurs in juxtaposition to the inflamed synovium or 
pannus. This vascular granular granulation tissue is composed of 
proliferating fibroblasts and a variable number of mononuclear cells and 
produce a large number of degradative enzymes, including collagenase and 
stromelysins. The cytokines IL-1 and TNF play an important role in 
stimulating the cells of the pannus to produce proteases. These cytokines 
may contribute to the local demineralization of bone by activating 
osteoclasts. Systemic manifestations of RA can be accounted for by release 
of inflammatory molecules from the synovium. These include IL-1, TNF, 
IL-6, which account for many of the manifestations of active RA.     
Clinical Manifestations: 
Articular Disease: 
                Pain in the affected joints, aggravated by movement, is the most 
common manifestation of established RA. Generalized stiffness is frequent 
and is usually greater after periods of inactivity. Morning stiffness of greater 
than 1- hour duration is an almost invariable feature of inflammatory 
arthritis and may serve to distinguish from non- inflammatory joint 
disorders.      
              Clinically, synovial inflammation causes swelling, tenderness and 
limitation of motion. Pain originates predominantly from joint capsule, 
which is abundantly supplied with pain fibers and is markedly sensitive to 
stretching or distention. Joint swelling results from accumulation of synovial 
fluid, hypertrophy of the synovium and thickening of the joint capsule. 
            Although inflammation can affect any diarthroidal joint, RA most 
often causes symmetric arthritis with characteristic involvement of certain 
specific joints such as the proximal interphalangeal and 
metacarpophalangeal joints. The distal interphalangeal joints are rarely 
involved. Axial involvement is limited to the upper cervical spine. 
Involvement of lumbar spine is not seen, and lower back pain cannot be 
ascribed to RA. On occasion, inflammation from the synovial joints and 
bursae of the upper cervical spine lead to atlantoaxial subluxation. With 
persistent inflammation, a variety of characteristic changes are seen, 
particularly in the hands.  
 
 
 
  
1. Radial deviation of the wrist with ulnar deviation of the digits, often 
with palmar subluxation of the proximal phalanges. (“Z” deformity)      
 
2. Hyperextension of the proximal interphalangeal joints with   
compensatory flexion of the distal interphalangeal joints. (Swan neck 
deformity) 
 
3. Flexion contractures of the proximal interphalangeal joints and 
extension of the distal interphalangeal joints. (Boutonniere deformity)     
 
4. Hyperextension of the first interphalangeal joint and flexion of the 
first metacarpophalangeal joint. 
 
5. Typical joint changes in the foot, including eversion at the hind foot, 
plantar subluxation of the metatarsal heads, widening of the forefoot 
hallux valgus and lateral deviation and dorsal subluxation of the toes. 
 
 
 
  
The 1987 Revised Criteria for the classification of RA     
 
 
        CRITERIA             DEFORMITY 
a. Morning stiffness Stiffness in and around the joints 
lasting 1 hour before maximal 
improvement  
b. Arthritis of three or more joint 
areas 
At least three joint areas observed 
by a physician simultaneously- 
right or left Proximal 
interphalangeal, 
metacarpophalangeal, wrist, 
elbow, knee, ankle and 
metatarsophalangeal joints.   
c. Arthritis of hand joints Arthritis of wrist, 
metacarpophalangeal or proximal 
interphalangeal joint. 
d. Symmetric arthritis Simultaneous involvement of the 
same joint areas on both sides of 
the body. 
e. Rheumatoid nodules Subcutaneous nodules over bony 
prominences, extensor surfaces or 
juxtaarticular regions observed by 
a physician 
f. Serum Rheumatoid Factor Demonstration of abnormal 
amounts of serum rheumatoid 
factor by any method for which 
the result has been positive in less 
than 5% of normal control 
subjects. 
g. Radiographic changes Typical changes of RA on postero 
anterior hand and wrist 
radiographs that must include 
erosions or unequivocal bony 
decalcification localized in or most 
marked adjacent to the involved 
joints.  
Four of seven criteria are required to classify a patient as having  
 
rheumatoid arthritis (RA). 
 
Patients with two or more clinical diagnosis are not excluded. 
 
             In 1987, the American College of Rheumatology developed revised 
criteria for the classification of RA. These criteria demonstrate a sensitivity 
of 91 to 94 % and a specificity of 89% for the diagnosis of RA. Although 
these criteria were developed as a means of disease classification for 
investigational purposes, they can be useful as guidelines for establishing the 
diagnosis. 
 
Extraarticular Manifestations: 
 
             Extra articular manifestations may precede the onset of articular 
symptoms. Predictors for the development of extra-articular manifestations 
include severe joint disease, a positive antinuclear antibody assay, IgA (but 
not IgG or IgM) RF, rheumatoid nodules, and certain HLA-DR haplotypes 8. 
Rheumatoid arthritis is a systemic disease with a variety of extraarticular 
manifestations. 
 
Rheumatoid Nodules: 
                                This develops in 20 to 30 % of patients with rheumatoid 
arthritis. They are usually found on periarticular structures, extensor surfaces 
or other areas subjected to mechanical pressure, but they can also develop 
elsewhere, including the pleura and meninges. Common sites include the 
olecranon bursa, the proximal ulna, the Achilles tendon and the occiput.  
 
Skin Abnormalities: 
                          Livedo reticularis is a blotchy, erythematous to purplish 
discoloration of the skin due to the presence of an obliterative cutaneous 
capillaropathy. This lesion is sometimes associated with the 
antiphospholipid-antibody syndrome; a hypercoagulable state linked to 
antiphospholipid antibodies and characterized by recurrent vascular 
thrombosis and second trimester miscarriages.  
                       Rheumatoid arthritis is one of the causes of pyoderma 
gangrenosum, a necrotizing, ulcerative, noninfectious neutrophilic 
dermatosis. Sweet's syndrome, a neutrophilic dermatosis usually associated 
with myeloproliferative disorders, viral infections, and drug reactions, also 
occurs in rheumatoid arthritis.9 Other complications include erythema 
nodosum, lobular panniculitis, atrophy of digital skin, palmar erythema, 
diffuse thinning (rice paper skin), and skin fragility.  
 
 
Hematological Abnormalities: 
             a. Anemia- Iron utilization is impaired. 
                                Iron deficiency 
                                Reduced Erythropoeitin 
                             
It is normally normocytic and normochromic, unless complicated by blood 
loss, poor nutrition, hemodilution, intercurrent infections. 
              b. Thrombocytosis and thrombocytopenia 
              c. Eosinophilia  
              d. Lymphadenopathy  
Felty’s syndrome: 
                This is defined as a combination of rheumatoid arthritis in 
combination with splenomegaly and leukopenia. The syndrome occurs in 
patients with long-standing, seropositive, nodular, deforming RA. There is 
also increased risk of bacterial infections and lymphoproliferative and other 
malignancies.  
  
Renal Manifestation 
         Renal disease is rare in patients with rheumatoid arthritis. When it does 
occur, it is often related to treatment with nonsteroidal anti-inflammatory 
drugs (NSAIDs), cryoglobulinemia, or vasculitis. Renal manifestations 
include glomerulonephritis, azotemia, interstitial nephritis, and papillary 
necrosis. Patients with secondary renal amyloidosis due to long-standing 
chronic inflammation may have proteinuria. 10.  
 
Hepatic Abnormalities:                       
                  Active RA may be associated with an increase in liver enzymes. 
(Especially serum aspartate aminotransferase and alkaline phosphatase). 
Liver involvement varies from portal fibrosis to nodular regenerative 
hyperplasia. 
 
 
Eye Abnormalities: 
           The Rheumatoid process involves the eye in less than 1% of patients. 
a. Episcleritis 
b. Scleritis 
c. Scleromalacia Perforans 
 
 
 
 
 
 
 
  
Rheumatoid Vasculitis: 
 
           It is seen in patients with severe RA and high titers of circulating 
Rheumatoid factor. In its most aggressive form, rheumatoid vasculitis can 
cause polyneuropathy and mononeuritis multiplex, cutaneous ulcerations 
and dermal necrosis, digital gangrene and visceral infarction. Myocardial 
Infarction secondary to rheumatoid vasculitis has been reported, as has 
vasculitic involvement of lungs, bowel, liver, spleen, pancreas, lymph nodes 
and testes. 
 
Pleuropulmonary Manifestations: 
Interstitial pulmonary fibrosis 
Pleural disease 
         Pleuritis with or without effusion 
         Sterile or septic empyema 
         Necrobiotic rheumatoid nodules associated with bronchopleural fistula 
         Pyopneumothorax 
Rheumatoid (Necrobiotic) Nodules; Pneumoconiotic nodules (Caplan’s 
syndrome) 
Bronchiolitis obliterans organizing pneumonia (BOOP) 
Airway disease 
           Bronchiolitis obliterans 
           Follicular bronchiolitis 
           Bronchiectasis 
           Upper airway dysfunction secondary to cricoarytenoid arthritis  
Respiratory tract infection, especially typical and atypical tuberculosis 
Drug induced lung disease 
          Penicillamine 
          Methotrexate 
          Gold 
Apical Fibrobullous disease 
Thoracic cage immobility 
Pulmonary vascular lesions  
Pulmonary Hypertension- Primary and secondary to lung disease 
 
Cardiac Manifestations: 
                Cardiac involvement occurs in the majority of patients with 
seropositive rheumatoid arthritis. The most common manifestation is 
pericarditis. Although symptomatic pericarditis is relatively uncommon, 
both random electrocardiographic evaluation in patients with RA and 
autopsy studies reveal evidence of pericardial inflammation in 50% of 
patients. Although it is usually asymptomatic, rheumatoid pericarditis can be 
associated with pericardial effusion and the development of acute or chronic 
pericarditis with tamponade. The restrictive pericarditis of rheumatoid 
arthritis responds poorly to medical therapy and generally requires 
pericardiectomy. Pericarditis usually occurs in seropositive patients with 
nodules.  
                   Myocardial disease resulting from nodular granulomatous 
lesions or more diffuse fibrosing lesions has been seen in RA. Non-specific 
myocarditis is usually a symptomatic and rarely affects cardiac size or 
function. Male patients with RA may suffer a greater frequency of 
congestive cardiac failure than persons without RA, and even in a 
symptomatic patient, left ventricular diastolic function more often impaired 
than in those without RA in spite of normal left ventricular systolic function. 
Abnormalities in the conduction pathways have also been described. 
Endocardial involvement may be diffuse, but it is rarely clinically 
significant.           
              Echocardiographic evidence for some degree of valve involvement 
is detected in about 30% of patients, but it is usually hemodynamically 
insignificant. Lesions typical of RA in the absence of symptomatic cardiac 
disease include posterior pericardial effusion, aortic root abnormalities and 
valvular thickening. However, a few patients develop valvular 
incompetence. Coronary arteritis can occur as part of systemic rheumatoid 
arthritis. Because myocardial and endocardial diseases associated with RA is 
usually a result of vasculitis and nodule formation, appropriate treatment of 
the underlying disease is necessary. RA itself may be an independent risk 
factor for coronary artery disease. It has been suggested that coronary artery 
disease may be associated with monoclonal proliferation of CD4 + CD 28 
null T cells in patients with or without RA in the absence of vasculitis- 
another mechanism by which coronary ischemia can occur.   
           Long-term survival of patients with rheumatoid arthritis (RA) is 
shorter compared with the general population or control subjects without 
RA.1 Among the different causes of death, increased mortality from heart 
disease with high prevalence of congestive cardiac failure was reported in 
many studies.1, 2 However, cardiac disease is often clinically silent and is 
rarely a severe life threatening complication in RA. Cardiac failure is the 
result of either systolic or diastolic dysfunction or both. Left ventricular 
diastolic dysfunction is usually attributable to common structural 
abnormalities such as hypertrophy or interstitial fibrosis and impaired 
myocyte relaxation resulting from ischemia.  
                   Diastolic dysfunction is defined as the deterioration of the 
ventricular filling capacity without any compensatory increase in the left 
atrial pressure. 11 Another definition is the abnormal ventricular filling defect 
causing cardiac output inadequacy. 12 In patients with diastolic dysfunction, 
the deterioration of ventricular dilatation (early diastole), decrease in 
compliance (early late diastole) or an external pressure in pericardium can 
lead to problems in ventricular filling. Cardiomyopathies, constructive 
pericarditis, ischemic heart diseases, volume overload (mitral insufficiency, 
arteriovenous fistulae), mitral and tricuspid valve stenosis may cause 
diastolic dysfunction. 13, 14 
                   In echocardiography, there are various methods measuring 
diastolic dysfunction. The early diastolic filling wave ‘E’, subsequently the 
deceleration phase and then the ‘A’ wave formed as a result of the atrial 
contraction are determined during the diastolic phase. 15 
                   Most researchers have measured the peak velocity of the E wave 
and the A wave by transmitral pulsed-wave Doppler and calculated the 
relation between these two parameters as the rate of E/A. When taken alone, 
normally E/A is bigger than 1; in late relaxation it decreases to below 1 and 
this is an indicator of diastolic dysfunction. 16, 17 The E/A rate can be 
measured as below 1 especially in most of the people over the age of 60–70 
years. 15 
                 The reasons of diastolic dysfunction in RA cannot yet be fully 
explained. It is thought to be linked with myocardial ischemia or cardiac 
autonomic neuropathy caused by cardiovascular disease, which is common 
in RA. Additionally, it is thought that in patients with RA, pericardial 
perfusion may cause diastolic filling defects by exerting external pressure on 
ventricles. In autopsy studies on RA, non-specific myocarditis, 
granulomatous lesions, secondary amyloidosis and coronary vasculitis 
were reported. These lesions may deteriorate the left ventricular diastolic 
filling. Prospective studies proved that long-lasting diastolic dysfunction 
increases the rate of mortality due to cardiac insufficiency. In a study 
assessing diastolic filling functions by calculating the rate of isovolumetric 
relaxation period and peak filling, a significant deterioration was detected in 
left ventricular filling in patients with RA, when compared with the 
control group. 18           
                 Some studies have shown that cardiovascular disease is the 
commonest cause of premature mortality in patients with rheumatoid 
arthritis (RA) 19. In RA, the risk of death caused by cardiovascular disease 
was considered to be doubled compared with an age-matched population 
20.
 Additional reports have confirmed an increased prevalence of 
cardiovascular complications in patients with RA 21, 22. del Rincon et al 21 
have observed that the higher incidence of cardiovascular complications 
in these patients was independent of the influence of traditional 
cardiovascular risk factors. With respect to this, they have recently 
confirmed the presence of endothelial dysfunction in long-term, actively 
treated patients with RA 23. As vascular endothelial dysfunction is closely 
linked to the development of atherosclerosis, this finding may, at least in 
part, explain the increased mortality observed in these patients 23.  
                Besides coronary complications, classic studies showed a high 
prevalence of congestive heart failure in RA 2, 23. A high incidence of 
myocardial, endocardial, and pericardial involvement also was reported in 
necropsy studies 2  
                 It is hypothesized that the systemic inflammation associated with 
rheumatoid arthritis (RA) promotes an increased risk of cardiovascular (CV) 
morbidity and mortality. In a population-based study from Mayo clinic of 
the risk of congestive cardiac failure in rheumatoid arthritis patients, they 
found that compared with persons without RA, patients with RA have twice 
the risk of developing CHF. This excess risk is not explained by traditional 
CV risk factors and/or clinical ischemic heart disease. 24 
            Thirteen years ago, Finnish investigators showed abnormalities in left 
ventricular diastolic function in 12 young men with RA without clinically 
evident cardiac disease compared with 14 healthy controls 18. Later, Italian 
investigators described the presence of diastolic abnormalities in both men 
and women with RA 25. Diastolic dysfunction was observed despite normal 
left ventricular systolic function, compared with matched controls. 
Abnormal relaxation was mainly responsible of the impairment in left 
ventricular filling 25.  
             More recently, a different group reported the presence of diastolic 
dysfunction in 32 Italians with RA without clinically evident cardiac disease 
26
. Similar abnormalities have been observed in patients with ankylosing 
spondylitis and psoriatic arthritis 27, 28. Thus, primary diastolic dysfunction is 
a finding that is present in different chronic inflammatory rheumatic 
diseases.  
             Because primary diastolic dysfunction is an important cause of heart 
failure, as it often is a silent alteration preceding systolic dysfunction 29, 
knowledge of this complication in patients with RA without clinically 
evident cardiac disease may be important to improve patient survival. A 
correlation between diastolic dysfunction and disease duration in active 
patients with RA has also been reported in one study. 30. 
           In literature, rheumatoid valvular involvement was reported as 6–62% 
in autopsy series. 31 In a study performed with the aim of determining the 
aetiologies of 1051 patients, who underwent surgery due to mitral stenosis, 
RA was detected only in two patients (less than 1%). 32 Thus, valvular 
involvement in RA usually is asymptomatic and number of cases that require 
surgery is relatively limited. In a study of RA patients for the determination 
of valvular involvement, the rate of mitral valvular involvement was 40%, 
aortic valve involvement 20% and variations in the aortic root was 34.3% 
and all these findings were evaluated to be significantly higher than the 
control group. 33 In another study, it was observed that there was no 
significant relation between valvular involvement and the disease duration. 
34
 In another research, it was detected that 25% of the patients with RA 
suffer from valvular involvement and it was found that especially the 
patients with valvular involvement had high levels of (66%) IgG 
anticardiolipin antibodies, but there was no significant difference in terms of 
valvular involvement between patients whose anticardiolipin antibodies 
were positive and negative. 35 
 
             
            Conduction defects were reported in rates of 8–10% in various 
studies. 34 In these studies, complex or different levels of heart blocks were 
defined. In postmortem studies, mononuclear cell infiltration, significant 
vascular degeneration and moderate fibroelastosis were detected in the 
conduction system. 36 On the other hand, though rarely, atrioventricular 
blocks may develop as a complication of methotrexate and chloroquine 
therapies. 37, 38 Nevertheless, methotrexate therapy can cause ventricular 
tachycardia. 39 In a study with a 24-hour ECG monitorization, arrhythmias 
were detected in 43 of 70 patients with RA, whereas arrhythmias were 
reported to be detected only at a rate of 6–8% with 12-leads standard ECG. 
 
             Pulmonary hypertension in Rheumatoid arthritis may be secondary 
to pulmonary fibrosis (derived from its structural alterations and chronic 
hypoxia) and to hyperviscosity 40 or it may occur isolated, similarly to 
primary pulmonary hypertension.  
 
             Pulmonary hypertension has been observed in patients with RA 7. 
Using Doppler echocardiography, a pulmonary artery pressure of 30 mm Hg 
or greater was found in 45 (31%) of 146 unselected patients with RA in 
England 7. In that series 21% of the patients had an estimated pulmonary 
artery systolic pressure of 30 mm Hg or greater without clinically evident 
cardiac disease 7.  
               With this background, we did a study to study the prevalence of 
echocardiographic abnormalities, diastolic dysfunction and pulmonary 
hypertension in rheumatoid arthritis patients and correlated them with the 
disease duration.    
 
 
 
      
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
                The study was carried out on 45 patients (nine men and 36 women, 
mean (SD) age 34.8 (6.7), range 21-50 years) attending the rheumatology 
out patient department of Madras Medical College and General Hospital 
with an established diagnosis of RA, as defined by the American 
Rheumatism Association 1987 criteria. Duration of the disease ranged from 
1 to 17 years. Informed consent was obtained from subjects enrolled and the 
study was approved by the local ethics committee. 45 normal subjects (nine 
men and 36 women, mean (SD) age 35.4 (6.5), range 23-52 years) were 
selected as controls.  
 
               None of the subjects included in the study had evidence of cardiac 
disease, hypertension, diabetes mellitus, chronic obstructive pulmonary 
disease, pulmonary tuberculosis or pulmonary thromboembolism as assessed 
by history, physical examination, Chest radiography and standard 12-lead 
ECG. In view of the radiation exposure involved in the study, patients were 
excluded if they were pregnant or planning a pregnancy. Patients with 
moderate mitral regurgitation, mitral stenosis or a left ventricular ejection 
fraction below 64% were considered to have a cardiac cause for their PASP 
and so were excluded. 
 
            All had been treated with nonsteroidal anti-inflammatory drugs  
(diclofenac, 100-150 mg/day) daily. All of them have been treated and were 
in treatment with 1 or more DMARD, including chloroquine, sulphasalazine, 
and methotrexate. Treatment with a DMARD was initiated when a diagnosis 
of RA was made. 
 
             Patients were considered seropositive if the rheumatoid factor (by 
nephelometry) was positive on at least 2 separate occasions during the 
course of the disease. 
 
               A questionnaire prepared noted the duration of RA, extra-articular 
complications, the use of current and previous disease-modifying drugs, 
corticosteroid use, and early morning joint stiffness. Questions were asked 
relating to previous chest disease, cough, dyspnea, sputum production, chest 
pain, weight loss and risk factors for respiratory disease, including smoking, 
medications, domestic pets and occupation. Cigarette consumption was 
evaluated in pack years (1 pack yr = 20 cigarettes/day for 1 yr). A detailed 
clinical examination was performed. All patients had venous blood taken for 
full blood count, renal and liver function, C-reactive protein and plasma 
proteins. Immunological investigations included rheumatoid factor (latex 
agglutination test) and antinuclear antibodies.  
 
             All patients underwent echocardiography, Electrocardiogram 
(ECG), chest radiography, High Resolution Computerized Tomography 
(HRCT) and full pulmonary function testing (PFT). Patients with pulmonary 
hypertension without significant lung disease were also evaluated for the 
presence of anticardiolipin antibodies.  
 
Echocardiography: 
                 Two-dimension and M mode echocardiography was performed 
with the patient in the left lateral position, using ALOKA echocardiogram. 
One senior cardiologist performed the echocardiography. Whenever 
possible, this cardiologist, who was blinded to clinical details, determined 
pulmonary artery pressure. The following variables were assessed: aortic 
root diameter, left atrial diameter, left ventricular end-diastolic diameter, left 
ventricular end-systolic diameter, thickness of the interventricular septum, 
thickness of the left ventricular posterior wall, and right ventricular end-
diastolic diameter. Fractional shortening and ejection fraction were 
calculated according to Simpson’s formula.  
 
           Special attention was paid to the structure of the mitral, aortic, 
tricuspid, and pulmonary valves (different grades of regurgitation and 
stenosis were assessed), and the pericardial space to detect pericardial 
effusion. 
 
                Doppler echocardiography was used to obtain transmitral flow 
from the apical four-chamber view. To record transmitral flow the sample 
volume was positioned at the tip of the leaflets of mitral valve. The 
following variables were examined as parameter of left ventricular filling: 
Peak of early diastolic (E) and late diastolic (A) flow velocity, E/A ratio, and 
isovolumic relaxation time (IVRT). When taken alone, normally E/A is 
bigger than 1; in late relaxation it decreases to below 1 and this is an 
indicator of diastolic dysfunction. 16, 17 We have taken E/A ratio of less than 
1 as suggestive of diastolic dysfunction. 
 
             Tricuspid regurgitation was identified in continuous-wave mode at 
the apex. The peak instantaneous drop in systolic pressure from the right 
ventricle to the atrium was calculated from the peak signal velocity of the 
tricuspid regurgitant signal by the simplified Bernoulli equation, P=4v2, 
where P is the trans-tricuspid gradient and v is the peak velocity measured.  
 
             The final estimate of the pulmonary artery systolic pressure was 
obtained by adding the patient's jugular venous pressure to the estimate of 
the trans-tricuspid gradient 41.     
 
Pulmonary function tests:      
              Pulmonary function tests comprised spirometry, static lung volume 
and flow loops. In all cases the pulmonary function tests were performed on 
the same day as the echocardiogram.  
 
Definitions 
Pulmonary hypertension:  
                    The gold standard for pulmonary artery pressure measurement 
is invasive right-heart catheterization. Pulmonary hypertension, defined by 
right-heart catheterization of the pulmonary artery is a pressure of 20 mmHg 
or greater at rest and at least 30 mmHg during exercise 42.  
     
                   Echocardiography has now been used widely in patients with 
cardiac disease. Reported correlations between Doppler and catheter 
measurements range from 0.89 to 0.97; the average standard error for 
systolic pulmonary artery pressure ranges from 5 to 9 mmHg, and 
interobserver variability is <3% 43-45. Similar to the study by Dawson et al, 
we have taken Denton et al.'s definition of pulmonary hypertension on 
Doppler echocardiography as an estimated PASP of 30 mmHg or greater.  
 
 
Significant lung disease: 
          Significant lung disease that could be causing pulmonary hypertension 
was defined as pulmonary function measurements outside the normal range: 
a forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) ratio of 
less than 65% or a vital capacity lung volume of less than 80% of the 
predicted value 46,47.  
 
 
 Pulmonary artery pressure control group: 
                   For the normal population, limited data are available on 
pulmonary artery pressure estimated by Doppler echocardiography. A study 
of 20 normal healthy adults by Vachiery et al. 48 using Doppler 
echocardiography found that the maximum estimated pulmonary artery 
pressure was 24 mmHg  
    
               To assess the diagnostic validity of the results of the 
echocardiogram, a control group for echocardiogram readings was 
incorporated into the study. Patients with RA were excluded. 
Echocardiography was undertaken with the same ALOKA echocardiogram 
by the same cardiologist who performed the echocardiography in the 
patients with RA.          
  
 
 
 
 
 
                   
STATISTICAL ANALYSIS 
 
                 Continuous data were described as mean and standard deviation 
(mean +/- SD), and categorical variables as numbers. Comparisons between 
2 categories were made using Student t test (2 tailed) for continuous 
variables. To analyze categorical data we performed the chi square test. 
Pearson correlation was used to correlate the continuous variables like 
disease duration and pulmonary artery pressure and parameters of diastolic 
dysfunction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
RESULTS 
 
                  The main demographic, clinical and laboratory features of the 45 
patients with RA without clinical evidence of cardiovascular disease are 
shown in Table 1. Women outnumbered men. [Figure 1] The mean age at 
the time of diagnosis was 34.82+ 6.67 years. During the course of the 
disease, extra-articular manifestations were observed in almost 58% (26) of 
the patients. Rheumatoid nodules were found in 10 patients, all of whom 
were rheumatoid factor positive.  
Table 1 Demography, Clinical and Laboratory features of 45 patients 
with RA 
        
                 Variable 
 
              Number (%) 
Mean age at the time of study (yr) + S .D 34.82 + 6.67 
Men/ Women 9/36 
Proportion of men 20 % 
Mean disease duration (yrs)  5.07 years 
 Extra articular manifestations 26 (57.78%) 
Rheumatoid factor positive 28 (62.22%) 
                    40 patients (88.89%) had sufficient Tricuspid regurgitation  
 
visible for their pulmonary artery pressure to be assessed by Doppler  
 
echocardiography. Contrary to the literature, Of note, only 1 patient with RA  
 
had mild pericardial effusion. The structural findings in for the RA patients  
 
are listed in table 2.  
 
 
Table 2 Structural Findings found on Echocardiography of patients 
with RA 
 
    Finding on Echocardiogram 
 
     Number of Patients (%) 
Aortic stenosis                2 (4.4%) 
Aortic regurgitation               7 (15.55%) 
Mitral regurgitation               12 (26.67%) 
Pericardial effusion                  1 (2.2%) 
Tricuspid regurgitation                40 (88.89%) 
Aortic root dilatation                 11 (24.44%) 
 
 
 
 Main Echocardiographic and Doppler Finding in Patients With RA: 
               
           The main echocardiographic and Doppler findings in this series of 
patients with RA without clinical evidence of cardiovascular disease are 
summarized in Table 3. The mean values of diameters in the left cavities 
were within the normal ranges. It was also the case for the mean left 
ventricular ejection fraction (Table 3).  
 
              Nodules were present in the aortic valve in 5 patients. Mild aortic 
regurgitation was found in 7 (15.55%) of 45 patients (Table 2). 19 (42.22%) 
of the patients exhibited left ventricular diastolic dysfunction (E/A <1) due 
to impaired relaxation  
 
Echocardiographic and Doppler Differences Between Patients With RA 
and Controls: 
             There was a significant difference between the two groups regarding 
the ventricular cardiac chamber dimensions, both end systolic and end 
diastolic compared to controls. (p< 0.05) But there was no difference 
between the ejection fraction and fractional shortening of the left ventricle. 
           
                   In RA patients, we found abnormalities of left ventricular filling   
characterized by increased late diastolic mitral filling velocity A cm/s 
(76.92+ 11.62 vs. 70.11+ 5.33,p=0.001), prolonged isovolumic relaxation 
time ms (75.77+ 8.13 vs. 70.43+ 2.94, p=0.001) and by a reduced E/A ratio. 
(0.98+ 0.23 vs. 1.09 + 0.11,p= 0.004) compared to controls. (Table 3)          
           
                  Moreover in the group of patients we found a relation between 
the isovolumic relaxation time and disease duration (r= 0.67, p=0.001), late 
diastolic mitral filling velocity A cm/s and disease duration (r= 0.61, 
p=0.001) and a negative correlation between the E/A ratio and disease 
duration. (r= -0.19, p=0.21) [Figure 2, 3, 4] 
          
            19 patients (42.22%) in the RA group had E/A ratio of less than 1and 
this was taken as an indicator of diastolic dysfunction. Among the control 
population, only 2 patients (4.44%) had evidence of diastolic dysfunction. 
Moreover the mean age of patients was 34.8 + 6.7 years and this age cannot 
explain the diastolic dysfunction. The RA patients with evidence of diastolic 
dysfunction were then compared with RA patients with E/A ratio more than 
1 and the results are summarized in table 4. 
  
Table 3   ECHOCARDIOGRAPHIC AND DOPPLER VARIABLES IN PATIENTS    
                                              AND CONTROL SUBJECTS 
 
 
 
  PATIENTS  N=45 CONTROLS  N=45    P Value 
Left Atrium 
Diameter (mm)  
 
   27.60 + 4.47 
 
   24.96+ 2.45 
 
   0.01 
Aorta Diameter 
(mm) 
 
   29.91+ 1.50 
 
   30.18+ 1.15 
 
   0.35 
Left Ventricular 
end diastolic 
dimension (mm) 
   50.04+ 3.78 
 
    45.99+ 3.42 
 
   0.001 
Left Ventricular 
end systolic  
Dimension (mm) 
 
   30.48+2.47 
 
    29.04+2.29 
   
   0.005 
Ejection Fraction 
(%) 
   70.72+ 2.26     70.58+ 1.94     0.75 
Fractional 
Shortening (%) 
    38.32+ 3.29     39.07+ 3.37     0.22 
Early Diastolic 
flow velocity E 
(cm/s) 
   
    73.32+ 9.04 
 
    76.32+ 5.59 
 
    0.06 
Late Diastolic flow 
velocity A (cm/s) 
    76.92+ 11.62 
    70.11+ 5.33    0.001 
Isovolumic 
Relaxation Time 
(ms) 
 
    75.77+ 8.13 
 
    70.43+ 2.94 
 
   0.001 
E/A      0.98+ 0.23     1.09 + 0.11    0.004 
Pulmonary Artery 
Pressure (mm of 
Hg) 
   
    27.49+ 12.66 
 
    20.40+ 8.88 
 
    0.003 
 
 
 
 
 
 
 
 
 
 
 
  
 
Differences between Patients with RA with and without Left 
Ventricular Diastolic Dysfunction 
 
         To further investigate the implication of the left ventricular diastolic 
dysfunction in patients with RA without clinically evident cardiovascular 
disease, we assessed whether patients with RA who had left ventricular 
diastolic dysfunction had some clinical or investigational peculiarities that 
might help identify these patients. 
 
         Rheumatoid factor was significantly positive in patients with RA with 
left ventricular diastolic dysfunction (89.5% versus 42.3%; P=0.02). 
However, no statistically significant differences in sex, presence of extra 
articular manifestations, cumulative prednisone dose were found (data not 
shown). Also there was a significant difference in the estimated pulmonary 
artery systolic pressure between patients with and without left ventricular 
diastolic dysfunction (32.47+ 12.09 vs. 23.85+ 12, p=0.02). 
 
 
 
 
 
 
  
 
 
 
 
Table 4   ECHOCARDIOGRAPHIC AND DOPPLER VARIABLES IN PATIENTS    
                WITH AND WITHOUT DIASTOLIC DYSFUNCTION 
 
 
 
 PATIENTS  (N=19) 
      [E/A < 1] 
PATIENTS (N=26) 
     [E/A > 1] 
   P Value 
Left Atrium 
Diameter (mm)  
 
   27.26 + 6.49 
 
   27.85+ 2.17 
 
   0.67 
Aorta Diameter 
(mm) 
 
   30.11+ 1.91 
 
   29.77+ 1.10 
 
   0.46 
Left Ventricular 
end diastolic 
dimension (mm) 
   53.17+ 2.33 
 
    47.75+ 2.88 
 
   0.001 
Left Ventricular 
end systolic  
Dimension (mm) 
   32.80+1.50  
    28.78+1.42 
   
   0.001 
Ejection Fraction 
(%) 
   70.71+ 1.73     70.73+ 2.61     0.97 
Fractional 
Shortening (%) 
    35.22+ 2.53     40.59+ 1.35     0.001 
Early Diastolic 
flow velocity E 
(cm/s) 
   
    65.18+ 4.94 
 
    79.27+ 6.24 
 
    0.001 
Late Diastolic flow 
velocity A (cm/s) 
    87.85+ 7.73 
    68.92+ 6.10    0.001 
Isovolumic 
Relaxation Time 
(ms) 
 
    83.57+ 5.34 
 
    70.07+ 3.94 
 
   0.001 
E/A      0.75+ 0.09     1.15 + 0.11    0.001 
Pulmonary Artery 
Pressure (mm of 
Hg) 
   
    32.47+ 12.09 
 
    23.85+ 12.00 
 
    0.02 
 
 
 
 
 
 
 
  
 
 
 
PULMONARY HYPERTENSION IN RA 
All RA patients  
             Forty-five RA patients underwent all the investigations. 40 (88.8%) 
RA patients had sufficient tricuspid regurgitation visible for their pulmonary 
artery pressures to be assessed by Doppler echocardiography. 
 
RA patients with raised pulmonary artery pressure 
             Twelve RA patients (26.7%) had a pulmonary artery pressure of 
more than 30 mmHg. [Table 5] No patient had impaired left ventricular 
function, as assessed by left ventricular ejection fraction, which could 
explain pulmonary hypertension. Chest HRCT showed that 4 patients had 
interstitial lung disease with a fibrosing alveolitis pattern. Among the 4 
patients, in three of these patients the lung disease was sufficiently severe to 
cause significant volume loss (as defined above, under significant lung 
disease) on pulmonary function testing. Clinically, 3 patients (6.7 %) of the 
RA population studied had pulmonary hypertension that was secondary to 
lung disease. So the remaining (9) 20 % of patients had pulmonary 
hypertension without lung disease evident on pulmonary function testing. 
[Table 6] 
                 The clinical features of the patients with primary pulmonary 
hypertension without lung or heart disease were compared with those of RA 
patients who had a pulmonary artery pressure below 30 mmHg. The findings 
are shown in the table 7. Significant difference was found between the two 
RA groups in age and disease duration. Patients with pulmonary 
hypertension had a higher mean age (39.16+ 5.18) vs. patients without 
pulmonary hypertension (33.53+ 6.38, p= 0.008), and it was statistically 
significant. Patients with pulmonary hypertension also had higher mean 
duration of disease (10+ 4.67 vs. 5.18+ 3.31, p value = 0.003). No 
significant difference was found between the two RA groups when sex, 
smoking, corticosteroid treatment were compared. Also the acute phase 
response as assessed by C-reactive protein did not differ significantly 
between the two groups. We subsequently investigated the patients with 
primary pulmonary hypertension for the presence of anticardiolipin 
antibodies, but none of the patients tested was found to have a significantly 
elevated concentration (normal range, IgG 0–9 GPL U/ml, IgM 0–4 MPL 
U/ml).   
         In the control group, 2 patients (4.5%) had pulmonary artery pressure 
above 30 mm of Hg. Both these patients had no secondary lung or cardiac 
disease. The pulmonary artery systolic pressure was higher in patients with 
RA (27.49 +/- 12.66 mm Hg) than in controls (20.40 +/- 8.88) (P =0.003). 
Incidence of pulmonary artery systolic pressure >30 mm Hg indicating 
pulmonary hypertension was significantly higher in patients with RA (26.7 
% versus 4.5 % in controls; P =0.03). [Table 7] Among these 3 patients 
(6.7%) had pulmonary hypertension that was secondary to lung disease. So 
the remaining 20 % of patients had pulmonary hypertension without lung 
disease evident on pulmonary function testing or cardiac disease. Among the 
12 patients with pulmonary hypertension, 7 patients (15.6%) had pulmonary 
artery pressure more than 40 mm of Hg, while 5 patients (11.1%) had 
pulmonary artery pressure between 30 and 40 mm of Hg indicating mild 
pulmonary hypertension. Among the 7 patients, 3 patients had significant 
lung disease sufficiently severe to cause significant volume loss and hence 
pulmonary hypertension. So 4 patients (8.9%) had moderate pulmonary 
hypertension (> 40 mm of Hg) primarily due to RA. 
 
 
 
             There was also a strong correlation between the pulmonary artery 
pressure and the disease duration (r= 0.68, p< 0.001) and a relationship was 
found between the pulmonary artery pressure and the age of the patient 
(r=0.32, p= 0.03). [Figure 6 and 7]             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 5 Pulmonary Artery Pressure in Rheumatoid Arthritis (RA) 
patients 
 
 
Pulmonary Artery 
Systolic Pressure 
Number of patients Number of patients with 
Primary pulmonary 
hypertension 
31-40 mm of Hg 5 (11.11%) 5 (11.11%) 
41-50 mm of Hg 6 (13.33%) 3 (6.6%) 
> 50 mm of Hg 1 (2.2%) 1 (2.2%) 
 
 
 
Table 6 PFT/HRCT findings in RA patients 
 
 
No of Patients PFT/ HRCT findings Pulmonary artery 
pressure 
3 Obstructive/ Fibrosing 
Alveolitis pattern 
42, 47, 44 
1 Normal/ Fibrosing 
alveolitis pattern 
48 
 
 
PFT is Pulmonary Function tests 
 
HRCT is high-resolution computerized tomography 
 
 
 
 
 
 
 
  
 
 
Table 7 Characteristics of RA patients according to pulmonary artery 
pressure 
 
 
(A) Continuous variables of RA patients 
 
 
 Primary 
pulmonary 
hypertension  
(N=9) 
Pulmonary artery 
pressure < 30 
mm of Hg (N= 
33) 
P value 
Age (yr) +/- SD 39.16+/-5.18 33.53+/-6.38 0.008 
RA Duration (yr) 10+/-4.67 3.31+/-5.18 0.0003 
Cigarette Pack yr 6.5+/-7.1 13.1+/- 14.2 0.21 
C-reactive 
protein (mg/l) 
30.2+/- 23.2 30.1+/- 24.1 0.72 
 
 
 
(B) Discrete Variables of RA patients 
 
 
 No of Patients 
with PPH (N=9) 
No of Patients 
with PAP < 30 
mm of Hg  
(N= 33) 
P value 
Rheumatoid 
Factor Positive 
8 28 0.86 
Anti nuclear 
antibody Positive 
3 11 0.93 
 
 
  
 
 
 
 
 
 
Table 8 Characteristics of RA patients and controls 
 
 
 Patients Controls P value 
Age (yr) +/- S.D 34.8 +/-6.7 35.4 +/-6.5 0.80 
Sex/ No. Of men  9 9 1 
PASP in mm of 
Hg 
27.49 +/- 12.66 20.40 +/- 8.88 0.003 
 30-40 mm of Hg 5 (11.1%) 0  0.03 
   > 40 mm of Hg 7 (15.55%) 2 (4.4%) 0.03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
             Figure 1 Sex Distribution of RA patients 
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Figure 2 Correlation between Diastolic dysfunction and Disease  
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Correlation coefficient r= -0.19 
 
Slope p=0.21 (not significant) 
 
 
 
 
 
 
 
 Figure 3 Correlation between Diastolic dysfunction (IVRT) and Disease  
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Correlation coefficient r= 0.67 
 
Slope p=0.001 
 
 
 
 
 
 
 Figure 4 Correlation between Mitral Filling Velocity (A) and Disease  
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Correlation coefficient r= 0.61 
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Figure 5 Pulmonary Artery Pressure distributions in RA patients 
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Figure 6 Correlation between pulmonary artery pressure and disease  
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Slope p < 0.001 
  
 
PAP is Pulmonary artery Pressure   
 
 
 
 
  
 
 
 
Figure 7 Correlation between pulmonary artery pressure and age                                                                                                                                          
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Correlation coefficient for study group r = 0.32 
  
Slope p = 0.03 
 
 
Correlation coefficient for control group r = -0.03 
                                                         
Slope p = 0.84 (not significant) 
 
DISCUSSION 
 
Cardiovascular Abnormalities in Rheumatoid Arthritis                
            In unselected patients with RA a wide spectrum of echocardiographic 
and Doppler abnormalities has been observed 7. An important step forward 
in our understanding cardiovascular disease in RA may be to confirm 
whether cardiac abnormalities also are present in actively and uniformly 
treated patients with RA in whom underlying cardiac disease or concomitant 
cardiovascular risk factors that might be implicated in the development of 
cardiac abnormalities have been excluded. 
                In our study of patients with RA from South India without 
cardiovascular risk factors or clinically evident cardiac disease, a number of 
echocardiographic abnormalities were observed. Besides valvular 
involvement, left ventricular diastolic dysfunction was observed in 19 of 45 
patients. (42.2%) 
                   Diastolic dysfunction is defined as the deterioration of the 
ventricular filling capacity without any compensatory increase in the left 
atrial pressure. 11 Another definition is the abnormal ventricular filling defect 
causing cardiac output inadequacy. 12 In patients with diastolic dysfunction, 
the deterioration of ventricular dilatation (early diastole), decrease in 
compliance (early late diastole) or an external pressure in pericardium can 
lead to problems in ventricular filling. Cardiomyopathies, constructive 
pericarditis, ischemic heart diseases, volume overload (mitral insufficiency, 
arteriovenous fistulae), mitral and tricuspid valve stenosis may cause 
diastolic dysfunction. 13, 14 
                   In echocardiography, there are various methods measuring 
diastolic dysfunction. The early diastolic filling wave ‘E’, subsequently the 
deceleration phase and then the ‘A’ wave formed as a result of the atrial 
contraction are determined during the diastolic phase. 15 
                   Most researchers have measured the peak velocity of the E wave 
and the A wave by transmitral pulsed-wave Doppler and calculated the 
relation between these two parameters as the rate of E/A. When taken alone, 
normally E/A is bigger than 1; in late relaxation it decreases to below 1 and 
this is an indicator of diastolic dysfunction. 16, 17 
                 Thirteen years ago, Finnish investigators showed abnormalities in 
left ventricular diastolic function in 12 young men with RA without 
clinically evident cardiac disease compared with 14 healthy controls 18. 
Later, Italian investigators described the presence of diastolic abnormalities 
in both men and women with RA 25. Diastolic dysfunction was observed 
despite normal left ventricular systolic function, compared with matched 
controls. Abnormal relaxation was mainly responsible of the impairment in 
left ventricular filling 25.  
              More recently, a different group reported the presence of diastolic 
dysfunction in 32 Italians with RA without clinically evident cardiac disease 
26.
 Similar abnormalities have been observed in patients with ankylosing 
spondylitis and psoriatic arthritis 27,28. Thus, primary diastolic dysfunction is 
a finding that is present in different chronic inflammatory rheumatic 
diseases.  
             Because primary diastolic dysfunction is an important cause of heart 
failure, as it often is a silent alteration preceding systolic dysfunction 29, 
knowledge of this complication in patients with RA without clinically 
evident cardiac disease may be important to improve patient survival. 
Similar to our study, a correlation between diastolic dysfunction and disease 
duration in active patients with RA has also been reported in one study. 30. 
            Our results indicate that patients with RA have a different mitral flow 
velocity pattern compared to controls. In the patients we found an increased 
mitral flow velocity pattern at atrial contraction and a decreased E/A ratio. 
As the subjects were selected to clinically exclude loading alterations and 
other factors that can affect diastolic filling, there is no reason to think that 
the two groups are not homogeneous and comparable.  
           Thus our results confirm diastolic abnormalities in RA patients and 
also point out that these abnormalities also concern left ventricular filling 
detected by echo Doppler examination of transmitral flow.  
         What is the clinical outcome of such abnormalities? Diastolic 
dysfunction has been recognized as a primary cause of CCF. In RA patients, 
an increased prevalence of congestive cardiac failure is well documented. 
Such an increased morbidity does not seem to be related to hypertension or 
ischemic heart disease. It could be due to more extensive involvement of the 
heart with consequent changes in left ventricular structure that might 
manifest themselves in abnormalities of left ventricular diastolic function, 
afterwards leading to systolic dysfunction. As no specific tissue typing 
studies were performed in our patients, we can only guess that these diastolic 
abnormalities could be caused by left ventricular structural alterations (i.e. 
an increase or modification of interstitial connective tissue within the 
myocardium)  
             In autopsy studies of RA, pericarditis was detected at a rate of 30–
50%, whereas the frequency of symptomatic pericarditis was reported only 
2–10%. 31, 35 In a prevalence study, pericardial effusion was detected at a 
rate of 6%. Nevertheless, pericarditis is the most common type of cardiac 
involvement reported in the literature. Clinically, pericarditis was reported in 
patients with high RF titers, subcutaneous nodules, anemia and high rate of 
sedimentation. 35 In a study of 39 patients, echocardiographic pericardial 
Involvement was detected in four patients; three of these had effusion, 
whereas one of them had pericardial adhesion. 49 In our study, pericardial 
effusion was detected in only 1 of 45 patients (2.2%). The reason could be 
that we see a different population and the susceptibility factors would be 
different. 
       In our study, we found a statistically significant correlation between 
disease duration and alteration of diastolic function expressed as late 
diastolic mitral filling velocity (A) and isovolumic relaxation time (IVRT).  
The relation between transmitral flow alteration and disease duration 
suggests a sub-clinical myocardial involvement with disease progression. 
This observation could be of a therapeutic benefit in sensitizing the doctors 
about the benefits of controlling the disease progression and periodic 
screening by echocardiography of RA patients. 
 
 
 
 
 
Pulmonary Hypertension in Rheumatoid Arthritis                  
               
              PHT is an increasingly recognized complication of the autoimmune 
rheumatic diseases, including RA 50. The largest series belongs to Dawson et 
al 7, who screened 146 RA patients with DE and found that 31% had PHT. 
When the RA patients with cardiopulmonary diseases were excluded; the 
frequency of PHT became 21% — approaching our figure 7. 
        Concurrence of rheumatoid arthritis and pulmonary hypertension is not 
common in clinical practice. Pulmonary hypertension may be an extra-
articular manifestation of rheumatoid arthritis or may be secondary to other 
diseases 51.  
                      All our patients were submitted to high-resolution computed 
tomography of the thorax and spirometry. As none of these tests showed 
evidence of other causes for increased pulmonary artery pressure, we 
considered this patient as having pulmonary hypertension secondary to 
rheumatoid arthritis. Lung biopsy was not done since it may have harmful 
complications. Reported lung biopsies of pulmonary hypertension secondary 
to rheumatoid arthritis usually show a mixed pattern of hypertrophy and 
fibroelastic proliferation of the media and the intimae of small- to medium-
sized pulmonary arteries 52. In the absence of vasculitis, these histological 
findings are identical to that of primary pulmonary hypertension 53. Chest 
HRCT performed on these patients identified early fibrosing alveolitis in 4 
patients in the pulmonary hypertension group. Without volume loss on 
pulmonary function testing, the fibrosing alveolitis is unlikely to be at a 
stage to be causing secondary pulmonary hypertension. Whether or not 
fibrosing alveolitis on HRCT predicts the rate at which pulmonary 
hypertension progresses are yet to be determined. 
                  Doppler echocardiography is both sensitive and specific for the 
diagnosis of pulmonary hypertension 33, 54 However; recently Arcasoy et al 55 
compared the PASP estimated by DE and measured by cardiac 
catheterization in 166 patients with advanced lung disease. Although the 
correlation was good (r~0.69, p<0.0001), they found that 52% of the PASP 
measurements using DE were inaccurate, and 48% of the patients were 
misclassified as having PHT if the diagnosis was based on DE alone. But his 
study was undertaken in patients with advanced lung disease and none of our 
patients had significant lung disease demonstrated on PFT/HRCT imaging. 
Impairment of left ventricular function can cause elevation of pressure on 
the left atrium and raise pulmonary artery pressure. It would seem unlikely 
that this is the cause of the raised pulmonary artery pressure, as patients with 
a reduced left ventricular ejection fraction have been excluded. As Doppler 
echocardiography and cardiac catheterization have been reported to have a 
correlation of between 0.89 and 0.97 in cardiac causes of pulmonary 
hypertension 56, 57, we have not undertaken catheterization of our RA 
patients. 
                   The limitations of our study were that other causes of possible 
primary pulmonary hypertension like porto-pulmonary hypertension, Human 
Immunodeficiency virus infections were not ruled out before ascribing 
pulmonary hypertension to be due to RA. HIV testing was not undertaken in 
view of the ethical considerations. How ever it would seem unlikely that this 
is the cause of the raised pulmonary artery pressure, as patients were 
asymptomatic for other features of this disease. Another limitation of our 
study was that we did not measure the serum viscosity, as pulmonary 
hypertension in RA has been rarely reported with hyperviscosity syndromes. 
40
 
                   One more significant new observation of our study, as compared 
to the study by Dawson et al was the statistically significant correlation 
between the disease duration and pulmonary artery pressure and age and 
pulmonary artery pressure. This difference could be attributed to the 
different race of population we see, where the involvement of the pulmonary 
vessels could be a manifestation as the disease duration increases and also 
may be related to yet unidentified susceptibility genes in our population. RA 
patients with pulmonary hypertension were older compared to patients 
without pulmonary hypertension. Also a positive relationship between age 
and pulmonary artery pressure raises an issue whether pulmonary 
hypertension develops as the RA patients become older and as the disease 
duration increases. Also there was a statistically significant difference in 
disease duration also, probably indicating patients with pulmonary 
hypertension had a longer duration of the disease. Also surprisingly no 
correlation was observed between the pulmonary artery pressure and age in 
control population. [Figure 7] 
 
                 This study continues to raise an important issue—we have found 
that 26.7% of hospital RA patients have pulmonary hypertension on 
echocardiography. In 6.7% of our RA patients this was due to lung disease. 
The remaining 20 % probably had primary pulmonary hypertension. Further 
research into the pathogenesis and progression of raised pulmonary artery 
pressure in RA patients is needed. It is possible that mild to moderate PHT 
may also contribute to the high incidence of cardiovascular related deaths in 
RA. The relationship between the pulmonary artery pressure and disease 
duration and age suggests a sub clinical involvement of the pulmonary 
vasculature with disease progression and may be relevant to the high 
incidence of cardiovascular deaths observed in patients with RA. Long-term 
follow-up is obviously necessary to ascertain the impact of mild to moderate 
PHT on the prognosis and mortality rate of RA patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CONCLUSION 
 
 
The following are the conclusions from the study 
 
 
1. Cardiovascular manifestations are common in Rheumatoid arthritis  
 
patients. 
 
2. The relation between transmitral flow alteration and disease duration 
suggests a sub-clinical myocardial involvement with disease 
progression and may be related to the high incidence of cardiovascular 
deaths in patients with RA. 
3. The relationship between the pulmonary artery pressure and disease 
duration and age also suggests a sub clinical involvement of the 
pulmonary vasculature with disease progression and may be relevant 
to the high incidence of cardiovascular deaths observed in patients 
with RA 
 
 
 
 
 
 
 
 PROFORMA 
 
CARDIOVASCULAR MANIFESTATIONS AND PULMONARY 
HYPERTENSION IN RHEUMATOID ARTHRITIS 
 
AIM: 
       To study the prevalence of left ventricular filling abnormalities and 
pulmonary hypertension in patients with rheumatoid arthritis without clinically evident 
cardiovascular manifestations. 
  
NAME: 
 
AGE: 
 
SEX: 
 
DISEASE DURATION: 
 
RHEUMATOID FACTOR: 
 
SMOKING STATUS: 
 
HISTORY OF PRESENTING COMPLAINTS: 
 
1.  COUGH                                                                                               YES/NO 
2.  EXPECTORATION                                                                            YES/NO 
3.  DYSPNEA                                                                                           YES/NO 
4.  ORTHOPNEA                                                                                     YES/NO 
5.  PND                                                                                                     YES/NO 
6.  CHEST PAIN                                                                                      YES/NO 
7.  PALPITATIONS                                                                                 YES/NO 
8.  SYNCOPE                                                                                           YES/NO 
9.  CYANOSIS                                                                                         YES/NO 
10.  WEIGHT LOSS                                                                                   YES/NO 
       11.    OTHER COMPLAINTS                                                                     YES/NO 
        12.   RAYNAUDS PHENOMENON                                                          YES/NO 
 
TREATMENT HISTORY: 
 
 
1. HISTORY OF NSAID INTAKE:                                                  YES/NO 
HOW MANY YEARS 
 
  2.            HISTORY OF INTAKE OF DMARD:                                          YES/NO  
                         HOW MANY YEARS            
 
 
  
GENERAL EXAMINATION 
 
• Conscious 
• Temperature 
• Pallor 
• Icterus 
• Cyanosis 
• Clubbing  
•  Lymphadenopathy  
• Pedal edema 
 
Pulse Rate:                                                          Blood pressure:                            
 
 
EXAMINATION OF SYSTEMS 
 
Cardiovascular System: 
CHEST WALL DEFORMITIES:                                                   YES/NO 
MURMURS                                                                                                     YES/NO 
ESM                                                                                                                  YES/NO 
EDM                                                                                                                  YES/NO 
PSM                                                                                                                   YES/NO 
RVH                                                                                                                   YES/NO 
 
Respiratory System: 
INSPIRATORY CREPTS:                                                                             YES/NO 
PLEURAL EFFUSION                                                                                   YES/NO 
 
Abdomen: 
 
SPLENOMEGALY                                                                                         YES/NO 
 
Central Nervous System: 
 
 
 
 
 
INVESTIGATIONS 
 
1.  COMPLETE BLOOD COUNT 
 
Hemoglobin 
Total Count 
Differential Count 
ESR 
 
2.  C REACTIVE PROTEIN 
 
3.  BLOOD GLUCOSE 
 
 
4.  BLOOD UREA 
 
5.  SERUM CREATININE 
 
6.  SERUM ELECTROLYTES 
 
 
7.  LIVER  FUNCTION TESTS 
 
               Serum bilirubin-   Total 
                                              Direct 
                                              Indirect 
                SGOT 
                SGPT 
                SAP 
                Serum Proteins- Total 
                                          Albumin 
                                           Globulin 
8.  ANA 
 
9.  ANTIPHOSPHOLIPID ANTIBODIES 
 
 
10. X-RAY CHEST PA VIEW 
 
             
12. ELECTROCARDIOGRAPY 
 
 
13. HRCT 
 
 
 
14. ECHOCARDIOGRAPHY (Inclusive of Doppler) 
   
1. Left atrial enlargement 
 
2. Right atrial enlargement 
 
3. Aortic regurgitation 
 
4. Aortic stenosis 
 
5. Aortic root dilatation 
 
6. Mitral regurgitation/Mitral valve prolapse 
 
7. Pericardial effusion 
 
8. Left ventricle ejection fraction (EF %) 
 
9. Fractional shortening (FS %) 
 
10. Tricuspid regurgitation 
 
11. Transmitral flow velocity (E/A Velocity) 
 
12. Wall motion abnormalities 
 
13. Isovolumic relaxation time 
 
14. Pulmonary artery pressure (PAP) 
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                         ECHOCARDIOGRAPHIC MEASUREMENTS IN 45 RHEUMATOID ARTHRITIS PATIENTS 
 
 
 
PATIENT 
S.NO AGE SEX 
DURATION 
OF 
DISEASE 
(Years) 
LEFT 
ATRIUM 
DIAMETER 
(mm) 
AORTA 
 (mm) 
LVED 
(mm) 
LVESD 
(mm) 
EF 
% 
 
FS 
% 
 
E 
cm/s 
 
A 
cm/s 
 
E/A IVRT (ms) RF 
PAP 
(mm of 
Hg) 
1 44 F 5 YEARS 21 27 57.2 33.2 71 40.3 60.2 86.8 0.75 72.3 YES 36 
2 38 F 8 YEARS 32 30 52.1 37.3 64.5 32.1 72.3 110.1 0.66 79 YES 39 
3 36 F 6 YEARS 30 28 50.2 31.2 70 39.8 79 88.4 0.9 78.2 YES 32 
4 24 F 2 YEARS 83 28 48.4 26.5 72 40.6 79.6 71.2 1.12 70.1 N0 0 
5 22 F 1 YEAR 22 28 47.2 25.8 74 39.2 80.8 69.2 1.17 69.1 N0 23 
6 44 M 3 YEARS 32 30 50.2 30.3 71 38.9 70.2 68.1 1.03 69.2 YES 27 
7 36 M 4 YEARS 30 32 47.4 29.2 69 42.3 72.4 70.1 1.03 69.5 N0 29 
8 28 M 2 YEARS 32 30 46.2 29.8 70 41.3 64.6 61.3 1.05 67.8 N0 26 
9 30 F 6 YEARS 28 26 56.4 33.1 70 38.2 61.2 89.6 0.68 82.9 N0 0 
10 32 F 7 YEARS 31 30 54.4 32.4 71 36.9 64.7 87.2 0.74 80.2 YES 39 
11 30 F 1 YEAR 28 30 46.2 28.3 70 41.3 80.6 64.2 1.25 70.3 N0 25 
12 30 M 4 YEARS 30 32 56.1 33.2 73 38.2 61.2 80.2 0.76 81.2 YES 26 
13 32 F 2 YEARS 26 29 48.2 29.5 70 40.1 80.1 70.2 1.14 70.2 YES 24 
14 38 F 1 YEAR 28 30 46.2 28.2 72 42.3 81.1 74.3 1.1 69.8 YES 0 
15 37 F 9 YEARS 30 32 56.2 33.6 71 34.2 60.1 92.4 0.65 89.6 YES 42 
16 42 F 3 YEARS 30 30 45.2 28.4 69 41.2 74.3 71.2 1.04 68.9 NO 0 
17 34 M 2 YEARS 29 31 47.1 28.3 71 40.1 80.2 68.9 1.16 68.3 NO 27 
18 32 F 2 YEARS 30 32 46.9 27.9 72 39.9 82.3 68.9 1.19 70.1 NO 28 
19 39 F 13 YEARS 34 32 54.2 34.5 70 35.9 61.1 98.9 0.62 90.2 YES 47 
20 42 M 4 YEARS 29 30 49.2 29.9 69 41.2 74.2 72.3 1.03 70.1 YES 29 
21 36 F 6 YEARS 3 32 51.3 33.2 72 35.4 64.3 90.2 0.71 88.9 YES 29 
22 38 F 4 YEARS 28 29 46.4 28.8 75 40.2 72.1 62.4 1.16 70.2 NO 29 
23 21 F 1 YEAR 27 29 44.5 26.1 76 41.1 88.4 60.1 1.34 66.1 NO 28 
24 25 M 2 YEARS 30 31 46.2 28.4 70 40.2 80.1 65.4 1.22 68.2 YES 23 
25 32 F 8 YEARS 30 33 54.2 32.1 71 32.4 64.2 87.4 0.73 87.6 YES 21 
26 30 F 1 YEAR 28 30 51.2 30.2 71 34.1 66.2 84.2 0.79 84.2 YES 20 
27 32 F 6 YEARS 29 30 48.1 27.6 70 39.5 80.2 75.2 1.07 71.2 YES 26 
28 30 M 2 YEARS 27 31 46.5 29.1 71 40.2 81.2 70.2 1.16 66.9 YES 21 
29 41 F 9 YEARS 28 29 54.2 33.1 70 33.5 69.6 80.2 0.87 84.6 YES 44 
30 36 F 5 YEARS 27 28 50.1 31.2 72 35.2 68.9 78.1 0.82 82.1 YES 23 
31 46 F 2 YEARS 28 30 47.4 29.3 68 39.2 83.1 72.1 1.15 67.5 NO 21 
32 29 F 4 YEARS 29 31 49.8 31.2 70 36.1 70.2 74.2 0.95 74.1 NO 29 
33 30 F 6 YEARS 29 30 51.2 32.4 71 34.3 62.5 86.4 0.72 80.1 YES 28 
34 48 F 3 YEARS 26 30 49.8 30.1 66 39.8 80.2 75.4 1.06 68.2 YES 29 
35 42 F 15 YEARS 26 32 54.2 32.2 72 32.4 62.3 90.1 0.69 88.8 YES 52 
36 38 F 4 YEARS 28 30 49.8 31.1 71 39.9 79.6 70.2 1.13 69.1 NO 26 
37 31 F 8 YEARS 25 29 52.1 32.8 71 32.9 66.2 88.4 0.75 86.4 YES 35 
38 30 F 7 YEARS 28 30 51.2 33.1 71 32.1 63.1 86.2 0.73 89.2 YES 29 
39 50 F 17 YEARS 26 28 58.3 31.2 64.2 36.9 92.2 88.2 1.04 87.2 YES 46 
40 42 F 16 YEARS 26 28 53.1 31.2 73 41.9 72.1 70.4 1.02 70.2 NO 48 
41 31 F 4 YEARS 27 30 47.1 28.5 71 41.1 74.2 62.1 1.19 76.3 YES 28 
42 38 F 7 YEARS 29 31 53.9 33.1 72 35.1 61.1 90.2 0.68 88.3 YES 46 
43 28 F 3 YEARS 26 29 45.9 28.8 70 42.1 84.5 60.2 1.4 69.2 NO 28 
44 37 F 2 YEARS 28 30 44.9 28.1 69.8 41.4 82.3 69.7 1.18 69.9 NO 29 
45 36 M 1 YEAR 26 29 45.1 27.9 75 43.5 90.4 60.5 1.49 68.2 YES 0 
 
 
